SiNtx Technologies Inc (SINT)

[boston745]

garbage can penny stocks do reverse splits. Real companies do forward splits

If Sintx was properly valued then reverse splits wouldnt occur TA. Its improperly valued, in part, because of price manipulation and naked shorting before/after offerings. The value of Sintx IP is well over $232m Zimmer paid for Hydrocel IP! Im putting together the short/naked short data since the last RS. There was no news to justify the 50% drops in price everytime an offering was announced/after it was closed. Im guessing the same thing will happen post 2024 RS especially if a 300:1 RS occurs. This is information SEC needs to look at IMO.

To show just how much Sintx Si3n4 is worth, one need only look at a comparable company Implex, acquired in 2003, to see how much Sintx Si3N4 is worth in the few markets that Implex Hydrocel (Zimmer's Trabecular Metal) is used in. Keep in mind that Si3n4 brings superior benefits with it compared to that of Trabecular Metal (biodegradable, antimicrobial, more osseointegrative, can be imbued and used as a coating in/on other materials), has a larger market reach (armor, industrial, antipathogenic, other medical products), and has not been mired in recalls and lawsuits.

Total acquisition costs of Implex was $108m upfront + $124.1 (96m+28.1) in cash earn-out payments from 2004-2006 for a grand total of $232.1m. Sintx tried to IPO for a valuation of around $225m in 2007 when it only had spinal product candidates and hip/knee candidates in early stages of R&D.

The pending acquisition of Implex gives the Company enhanced flexibility in the development of products using Trabecular Metal Technology, which the Company believes has significant potential in orthopaedic reconstructive and spinal product applications.

The markets referenced here in Zimmers 10k are just a couple of markets Sintx Si3n4 can be used in.

Each share of Implex stock will be converted into the right to receive cash having an aggregate value of approximately $108 million at closing and additional cash earn-out payments that are contingent on the growth of Implex product sales through 2006.

We have paid $96.0 million of earn-out payments through December 31, 2005. We estimate remaining payments, which will occur in 2006, to be in a range from $30 million to $40 million.

In 2006, we made a final payment of $28.1 million pursuant to the terms of the Implex acquisition agreement for contingent earn-out payments.

Quote Sources:
https://www.sec.gov/Archives/edgar/data/1136869/000095013704001881/c83286e10vk.htm
https://www.sec.gov/Archives/edgar/data/1136869/000095013706002478/c02799e10vk.htm
https://www.sec.gov/Archives/edgar/data/1136869/000095013707002904/c12593e10vk.htm

Sintx 2016 10k

Together with a strategic partner, we have initiated biomechanical testing of our solid silicon nitride femoral heads. The results of this test will be released in 2017

This quote indicates the results of testing of their femoral head with a strategic partner will be released in 2017.
Those results were released testing Sintx Femoral head against Biomet's E1 liners. Thus Zimmer Biomet, or any of its subsidiaries, is Sintx strategic partner in this testing.

Amedica and Zimmer-Biomet (Tokyo Office) provided the femoral heads and acetabular liners; however, neither company actively sponsored the research

2016 10-k pg 13: https://www.sec.gov/Archives/edgar/data/1269026/000149315217010752/form10-k.htm
2017 results: https://ir.sintx.com/news-events/press-releases/detail/95/amedica-announces-results-of-independent-femoral-head-wear